European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"[⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study","authors":"Shengyan Liu,Xin Zhang,Ruochen Li,Ziren Kong,Xi-yang Cui,Zhu Li,Cong Shi,Dongxiao Bian,Yihan Zhao,Qijun Li,Yijin Pan,Zhaohui Zhu,Zhibo Liu,Shaoyan Liu,Yansong Lin","doi":"10.1007/s00259-026-08150-4","DOIUrl":"https://doi.org/10.1007/s00259-026-08150-4","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"176 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer","authors":"Claus Madsen,Helle D. Zacho,Rasmus Bisbjerg,Dan Fuglø,Peter B. Østergren","doi":"10.1007/s00259-026-08148-y","DOIUrl":"https://doi.org/10.1007/s00259-026-08148-y","url":null,"abstract":"Abstract Purpose International guidelines recommend assessment for bone metastases in patients with high-risk prostate cancer (PC) and those with unfavourable intermediate-risk disease. These recommendations are largely based on studies using planar bone scintigraphy. We aimed to assess the diagnostic accuracy of [ 18 F]sodium fluoride ([ 18 F]NaF) PET/CT in newly diagnosed PC. We also evaluated the clinical utility of routine bone imaging in patients with unfavourable intermediate-risk disease and International Society of Urological Pathology grade group (ISUP GG) 3. Methods This retrospective single-center study included 734 consecutive patients with newly diagnosed PC who underwent [ 18 F]NaF PET/CT for primary staging. Patients were classified according to the current European Association of Urology risk classification, with the intermediate-risk subgroup restricted to patients with ISUP GG 3. All scan reports were retrospectively reviewed, and patient-level findings regarding bone metastases were validated against a reference standard based on follow-up imaging and clinical data. Sensitivity, specificity, and predictive values were calculated. Results Of the 734 patients, 607 (83%) had high-risk disease and 127 (17%) had intermediate-risk disease with ISUP GG 3. Overall, bone metastases were detected in 225 patients (31%). Among high-risk patients, 224 (37%) had bone metastases, whereas only 1 of 127 intermediate-risk patients (0.8%) had bone metastases on [ 18 F]NaF PET/CT. Follow-up identified one additional potential false-negative case in the intermediate-risk group. Among patients with a conclusive reference standard ( n  = 689), sensitivity and specificity were 0.90 and 0.99, respectively. Conclusion [ 18 F]NaF PET/CT demonstrates high diagnostic accuracy for the detection of bone metastases in newly diagnosed PC. However, given the very low prevalence of bone metastases, its clinical utility in patients with unfavourable intermediate-risk disease and ISUP GG 3 appears limited.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"59 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148895940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed total-body [18F]FDG PET/CT demonstrates systemic vascular inflammation after concurrent chemoradiotherapy in patients with head and neck cancer","authors":"Guobing Liu,Yasser G. Abdelhafez,Brahim Mehadji,Martina Di Franco,Benjamin A. Spencer,Siqi Li,Fatma Sen,Jinger Yu Sun,Shyam Rao,Abass Alavi,Hongcheng Shi,Guobao Wang,Lorenzo Nardo","doi":"10.1007/s00259-026-08160-2","DOIUrl":"https://doi.org/10.1007/s00259-026-08160-2","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"27 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis","authors":"Samuel M. Vorbach, Thomas Seppi, Giulia Santo, Irene Virgolini, Ute Ganswindt, Michael Keilholz, Sarah Frederike Brose, Jozefina Casuscelli, Konrad Klimek, Rudolf A. Werner, Nina-Sophie Schmidt-Hegemann, Claus Belka, Christian Trapp, Paul Rogowski","doi":"10.1007/s00259-026-08147-z","DOIUrl":"https://doi.org/10.1007/s00259-026-08147-z","url":null,"abstract":"Purpose PSMA PET/CT has transformed the detection of nodal recurrence after radical prostatectomy, yet real-world evidence on long-term outcomes of PSMA PET/CT-guided salvage elective nodal radiotherapy (ENRT) remains limited. This study evaluated oncological outcomes of PSMA PET/CT-guided salvage ENRT in a bi-institutional cohort with extended follow-up. Methods We retrospectively analysed 179 patients who received PSMA PET/CT-based ENRT for nodal recurrence after radical prostatectomy at two tertiary centres between 2014 and 2024. Patients with pelvic and/or paraaortic lymph node metastases were included. The primary endpoint was metastasis-free survival (MFS); secondary endpoints included biochemical progression-free survival (BPFS) and overall survival (OS). Survival outcomes were estimated using the Kaplan–Meier method, and prognostic factors were assessed using Cox regression analysis. Results Of the 179 patients, 104 (58.1%) had true biochemical recurrence after radical prostatectomy, whereas 75 (41.9%) had PSA persistence. After a median follow-up of 60.3 months, 5-year MFS and BPFS rates were 74.3% and 62.3%, respectively, in patients with true biochemical recurrence, compared with 61.2% and 56.4% in the overall cohort. In multivariable analyses of the entire cohort, concomitant ADT was associated with improved MFS (HR 0.36, <jats:italic>p</jats:italic> &lt; 0.001) and BPFS (HR 0.26, <jats:italic>p</jats:italic> &lt; 0.001), compared with no ADT. PSA persistence after surgery was associated with worse outcomes (MFS: HR 2.72, <jats:italic>p</jats:italic> &lt; 0.001; BPFS: HR 2.09, <jats:italic>p</jats:italic> = 0.005). Conclusion PSMA PET/CT-guided salvage ENRT predominantly combined with ADT provides durable long-term disease control in patients with nodal recurrence in routine clinical practice. In patients with true recurrence after radical prostatectomy, the 5-year MFS rate was 74.3%, approaching outcomes reported in prospective trials. However, the absence of systematically collected clinician-assessed toxicity and patient-reported outcomes precludes a reliable assessment of treatment tolerability.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"5 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148884000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CEA-targeted fluorescence endoscopy for the detection of high-grade dysplasia and early invasive rectal cancer: A proof-of-concept trial","authors":"M. I. Warmerdam, T. H. Dijkhuis, D. J. G. Linders, C. M. W. Pesch, A. S. L. P. Crobach, A. Matoshi, K. Basiliya, S. H. van den Berg, F. Cailler, K. C. M. J. Peeters, F. A. Holman, J. S. D. Mieog, A. L. Vahrmeijer, D. E. Hilling, J. J. Boonstra","doi":"10.1007/s00259-026-08155-z","DOIUrl":"https://doi.org/10.1007/s00259-026-08155-z","url":null,"abstract":"Purpose Accurate recognition of high-grade dysplasia (HGD) and early invasive carcinoma (IC) within colorectal polyps is essential for selecting the preferred local resection technique. However, optical endoscopic diagnosis can be challenging, particularly in large and advanced polyps. This study investigates whether carcinoembryonic antigen (CEA)-targeted near-infrared fluorescence (NIRF) imaging can distinguish polyps containing HGD/IC from polyps solely containing low-grade dysplasia (LGD), given prior evidence of CEA overexpression in HGD/IC relative to LGD. Methods Patients scheduled for local en-bloc endoscopic resection of advanced rectal polyps were included in the study and received 5 mg or 10 mg intravenous SGM-101, a CEA-targeted fluorescent agent. In vivo imaging was performed using a rigid Quest-Olympus NIRF-endoscope, followed by ex vivo whole-specimen and bread-loaf imaging using the PEARL imaging system. The primary endpoint was the NIRF tumour-to-low-grade-dysplasia ratio (TDR; HGD/IC divided by LGD) performed on bread loafs, as this method enabled direct pathological correlation. Secondary endpoints included dose-finding as well as sensitivity and specificity for detecting HGD/IC. Results A total of 22 patients were included, with 9/22 containing LGD only and 13/22 containing HGD/IC. Eleven patients received 10 mg and 11 received 5 mg SGM-101. Ex vivo bread-loaf imaging showed a median (IQR) TDR of 1.7 (1.3–2.9), with higher values in the 10 mg group of 2.5 (2.0-3.5) compared to the 1.3 (1.2–1.6) in the 5 mg group ( <jats:italic>p</jats:italic> = 0.023). The sensitivity for detecting HGD/IC was 86% (2 false-negatives), and specificity was 88% (1 false-positive). Conclusion Although with limited sample size, this study demonstrates proof-of-concept of CEA-targeted NIRF-imaging in differentiating HGD/IC bearing polyps from completely benign LGD polyps. Clinical utility, including its impact on treatment decision-making and patient outcomes, remains to be demonstrated in future, larger prospective studies. Clinical trial registration number NCT06280690.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"75 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148883654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of D-SPECT-derived myocardial flow reserve in detecting coronary microvascular disease and predicting outcomes after complete revascularization: a two-center pilot study.","authors":"Rong Wang, Jinlu Bai, Ping Xie, Haijun Wang, Xiaobo Wang, Zhilin Gao, Yanjun Chen, Hongzhi Mi, Wei Dong","doi":"10.1007/s00259-026-08162-0","DOIUrl":"https://doi.org/10.1007/s00259-026-08162-0","url":null,"abstract":"<p><strong>Purpose: </strong>This two-center prospective study sought to evaluate whether D-SPECT-derived myocardial flow reserve (MFR) can identify coronary microvascular disease (CMD) and predict major adverse cardiac events (MACE) in patients who had undergone complete revascularization by percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>We enrolled 174 patients with angiographically confirmed complete revascularization post-PCI. Global and regional MFR were quantified using dynamic D-SPECT at rest and during pharmacological stress. CMD was defined as global or territorial MFR < 2.0 in the absence of > 50% epicardial stenosis. The primary endpoint was major adverse cardiac events (MACE), defined as a composite of all-cause death, myocardial infarction, unscheduled coronary revascularization, stroke, heart failure hospitalization, and rehospitalization for angina pectoris. Multivariable Cox regression and reclassification analyses (NRI/IDI) were used to assess prognostic value.</p><p><strong>Results: </strong>Over a median follow-up of 12 months (interquartile range, IQR 7-21 months), 42 patients (24.1%) experienced MACE. Patients with CMD had significantly higher MACE rates (log-rank χ²=11.375, P = 0.001). After multivariate adjustment for cardiovascular risk factors and abnormal myocardial perfusion imaging, CMD remained an independent predictor of MACE (HR = 2.46; 95%CI: 1.27-4.76; P = 0.007). Regional MFR provided significant incremental prognostic value over global MFR (NRI = 0.524, 95%CI: 0.202-0.821; IDI = 0.036, 95%CI 0.007-0.067). The association between CMD and MACE was consistent across all prespecified subgroups.</p><p><strong>Conclusion: </strong>In this two-center cohort of patients with complete revascularization after PCI, D-SPECT-derived CMD is associated with a > 2-fold increased risk of future MACE, independent of traditional risk factors and perfusion abnormalities. Regional MFR provides incremental prognostic value beyond global MFR. These findings are exploratory and warrant validation in multi-center studies with longer follow-up and comparisons with invasive measurements.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental finding of central pontine myelinolysis on [¹⁸F]FDG PET/CT.","authors":"Teresa Antonia Kiener, Tobias Salzmann, Gundula Rendl, Mohsen Beheshti, Christian Pirich","doi":"10.1007/s00259-026-07923-1","DOIUrl":"10.1007/s00259-026-07923-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6139-6141"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep integration of clinical metadata with [¹⁸F]FDG PET/CT imaging for histological subtyping in non-small cell lung cancer: a multi-center study.","authors":"Jucheng Zhang, Xiaohui Zhang, Jing Wang, Han Hao, Daoyan Hu, Kangjun Hu, Xuena Li, Yaming Li, Guanghui Liu, Rong Tian, Weiming Wu, Xiaofen Ma, Yile Huang, Chentao Jin, Yan Zhong, Mei Tian, Hong Zhang","doi":"10.1007/s00259-026-08010-1","DOIUrl":"10.1007/s00259-026-08010-1","url":null,"abstract":"<p><strong>Purpose: </strong>To develop and validate a multimodal deep learning framework that integrates clinical metadata with [¹⁸F]FDG PET/CT imaging to resolve overlapping metabolic phenotypes. The primary objective is the histological subtyping of non-small cell lung cancer (NSCLC), utilizing binary clinical staging (early vs. advanced) strategically as an auxiliary regularization task.</p><p><strong>Methods: </strong>A multi-center surgical NSCLC cohort (n = 780) was partitioned into a development set (n = 675) and an independent external test set (n = 105). The framework first utilized a 3D Transformer for bounding-box-based tumor localization. Subsequently, a multi-task network employed Feature-wise Linear Modulation (FiLM) to dynamically inject clinical metadata into the visual backbone.</p><p><strong>Results: </strong>For histological subtyping of adenocarcinoma versus squamous cell carcinoma, in the validation cohort, the proposed multimodal framework achieved the highest area under the receiver operating characteristic curve (AUC) of 0.894 (95% CI: 0.813-0.959), significantly outperforming the conventional radiomics baseline (AUC = 0.796, DeLong test P = 0.017) and the clinical-only baseline (AUC = 0.759, P = 0.004). On the internal test set, the multimodal model maintained an AUC of 0.832 (95% CI: 0.744-0.906), outperforming competing models numerically, though differences did not reach statistical significance (all P > 0.11). On the independent external test cohort, the multimodal framework demonstrated superior cross-center stability, maintaining an AUC of 0.787 (95% CI: 0.687-0.876). On the external cohort, the between-model AUC differences did not reach statistical significance against the clinical-only model (AUC of 0.740, P = 0.480) or the image-only model (AUC of 0.685, P = 0.082). Nevertheless, the multimodal framework achieved the highest F1-score and yielded the most optimal net clinical benefit across a wide range of threshold probabilities in decision curve analysis. For the intrinsically challenging auxiliary staging task, the unguided image-only network exhibited severe vulnerability, however, the FiLM-based multimodal mechanism effectively enhanced diagnostic capacity by employing systemic clinical priors, improving the AUC to 0.656.</p><p><strong>Conclusion: </strong>Combining 3D detection with an early clinico-biological fusion strategy effectively enhances NSCLC characterization on [¹⁸F]FDG PET/CT, which has the potential to mitigate the limitations of single-modality imaging in resolving diagnostically ambiguous cases characterized by overlapping [¹⁸F]FDG uptake phenotypes, thereby providing a non-invasive decision-support tool in the precision management of NSCLC.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6520-6535"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dopaminergic nigrostriatal vulnerability in Parkinson's Disease with diabetes: evidence from severity-matched cohorts.","authors":"Alice Galli, Cinzia Zatti, Alessandro Lupini, Silvia Paola Caminiti, Andrea Rizzardi, Silvia Lucchini, Francesco Bertagna, Barbara Paghera, Tiago Fleming Outeiro, Daniela Perani, Alessandro Padovani, Andrea Pilotto","doi":"10.1007/s00259-026-08011-0","DOIUrl":"10.1007/s00259-026-08011-0","url":null,"abstract":"<p><strong>Purpose: </strong>Diabetes Mellitus (DM) has been recognized as a potential risk factor and disease-modifier in Parkinson's Disease (PD), being associated with worse motor and cognitive outcomes, and altered susceptibility of neural pathways. This study investigated the impact of DM on nigrostriatal dopaminergic vulnerability independently of disease severity in drug-naïve PD patients.</p><p><strong>Methods: </strong>This study analyzed two independent cohorts of PD patients (multi-center PPMI n = 174, single-center UniBS n = 95). Patients with and without DM were first compared and then matched for age, sex, and clinical severity. All patients underwent baseline ¹²³I-FP-CIT imaging to quantify dopamine transporter binding. Dopaminergic binding, neural reserve index and molecular connectivity patterns were compared between severity-matched groups.</p><p><strong>Results: </strong>Patients with DM were older, predominantly male, and exhibited worse non-motor and cognitive symptoms. After severity matching, PD-DM exhibited more preserved nigrostriatal dopamine uptake compared to PD-n. PD-DM also showed fewer nigrostriatal dopaminergic connectivity alterations (10% vs. 21%) and reduced neural reserve index in the left putamen and - only in the single-center cohort- whole striatum.</p><p><strong>Conclusion: </strong>In drug-naïve PD patients, comorbid diabetes is associated with comparable clinical severity despite milder dopaminergic loss. This suggests an increased dopamine system vulnerability linked to DM, reducing the efficiency and compensatory mechanisms of nigrostriatal dopaminergic networks in PD.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6274-6288"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detailed pharmacokinetic features of a novel bis-boron ¹⁸F-trifluoroborate acid in healthy volunteers: comparable and additional values of total-body PET-imaging-derived analysis.","authors":"Guobing Liu, Hongrong Xu, Jing Lv, Yunze Xie, Lichao Zhang, Denis Agostini, Florent L Besson, Axel Rominger, Akram Al-Ibraheem, Jiefu Zheng, Lorenzo Nardo, Xuening Li, Hongcheng Shi","doi":"10.1007/s00259-026-08004-z","DOIUrl":"10.1007/s00259-026-08004-z","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize the systemic and organ-specific pharmacokinetics (PK) of a novel bis-boron tracer, [¹⁸F]BBPA, using total-body PET imaging in comparison with conventional blood sampling.</p><p><strong>Methods: </strong>Ten healthy volunteers underwent 60-minute dynamic total-body [¹⁸F]BBPA PET, followed by three static scans (up to 240 min p.i.), alongside 11 venous blood sampling. Regions of interest were drawn on PET in their right atrium, superior vena cava (SVC), and inferior vena cava (IVC) to obtain image-derived blood time-activity curves (TACs), as well as in major organs to obtain tissue TACs. PK parameters of [¹⁸F]BBPA were assessed using both blood samples and image-derived blood TACs. Additionally, tissue TACs were analyzed for organ-specific PK and fitted with an tissue-compartment models for kinetic rates of [¹⁸F]BBPA.</p><p><strong>Results: </strong>[¹⁸F]BBPA exhibited rapid clearance (6.58 ± 0.57 L/h, a short elimination half-life (186.48 ± 30.29 min), and a volume of distribution of 29.22 ± 3.52 L. Image-derived PK results were comparable to those obtained from blood sampling, with the relative differences < 13% for SVC and < 15% for IVC. Imaging-derived method captured higher C_max and shorter T_max, primarily due to its superior temporal resolution. Organ-specified PK revealed low tissue affinity (partition coefficient < 1.0 in most organs) and minimal metabolic trapping (k₃ < 0.06 min^- 1 and k₂ > K₁ in the majority of organs).</p><p><strong>Conclusion: </strong>[¹⁸F]BBPA exhibits favorable PK properties, including rapid distribution, low normal-tissue affinity, and quick clearance. Total-body PET-image-derived method provides a reliable, non-invasive alternative to conventional blood sampling while offering additional, detailed organ-level kinetic insights.</p><p><strong>Clinical trial registration: </strong>This is a phase I clinical trial approved by the National Medical Products Administration of China and was registered at www.chinadrugtrials.org.cn (CTR20233997).</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6684-6696"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}